DEFA14A: Novartis to Acquire Avidity, Spin Off Cardiology Unit

Novartis AG plans to acquire Avidity Biosciences, Inc., while Avidity's early-stage precision cardiology programs will be spun off into a new independent entity, Atrium Therapeutics, Inc.

Summary

• Novartis AG, through its indirect wholly owned subsidiary Ajax Acquisition Sub, Inc., proposes to acquire Avidity Biosciences, Inc.
• Avidity will become an indirect wholly owned subsidiary of Novartis following the merger.
• Prior to the merger, Avidity will undergo a pre-closing reorganization, spinning off its early-stage precision cardiology programs and certain collaboration agreements into a new wholly owned subsidiary, Bryce Therapeutics, Inc. (renamed Atrium Therapeutics, Inc. or SpinCo).
• SpinCo will either distribute its shares to Avidity stockholders on a pro rata basis (1 share of SpinCo Common Stock per 10 shares of Avidity common stock) or be sold to a third party.
• Following the Spin-Off, Avidity will have no continuing ownership interest in SpinCo.
• The Spin-Off includes assets triggering a right of first negotiation with an existing collaboration partner, which was notified concurrently with the merger announcement.
• This filing serves as preliminary communication regarding the merger and spin-off, with a definitive proxy statement to be filed by Avidity.

Sentiment

Score: 7

Explanation: The filing announces a significant acquisition by a major pharmaceutical company and a strategic spin-off, indicating strong interest in Avidity's core assets. Management comments from Novartis CEO are highly positive regarding Avidity's science and people. However, the transaction is subject to customary closing conditions and inherent risks, which introduces some uncertainty.

Positives

• Avidity's AOC platform and late-stage programs in DM1, FSHD, and DMD are recognized as remarkable and transformative by Novartis CEO.
• Novartis intends to collaborate and partner with Avidity, prioritizing business continuity and preserving Avidity's capabilities.
• Avidity stockholders will receive consideration for their shares in the merger and potentially shares in the new independent SpinCo or proceeds from its sale.
• The transaction allows Avidity's precision cardiology programs to continue development under SpinCo, potentially as a separate, independent company.

Risks

• Conditions to closing the transactions (regulatory approvals, Avidity stockholder approval) may not be satisfied on the expected timetable or at all.
• Risks and costs associated with implementing the SpinCo separation, including potential delays or changes to the business configuration.
• The sale of certain SpinCo assets is subject to a third-party right of first negotiation.
• Potential for competing offers or acquisition proposals.
• Disruption to Novartis's and/or Avidity's businesses, including relationships with employees, business partners, or governmental entities, due to the transactions.
• The transactions may be more expensive to complete than anticipated.
• Stockholder litigation in connection with the transactions could result in significant costs.
• Diversion of management's attention from ongoing business operations.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.
• No guarantee that Avidity's investigational products will be submitted or approved for sale or any additional indications, or that its AOC platform will produce commercially valuable products.
• No guarantee that the expected benefits or synergies from the transactions will be achieved.

Future Outlook

The future outlook centers on the successful completion of the proposed merger between Avidity and Novartis, subject to regulatory and stockholder approvals. Concurrently, Avidity's early-stage precision cardiology programs will be separated into Atrium Therapeutics, Inc. (SpinCo), which will either be distributed to Avidity stockholders or sold to a third party, establishing it as an independent entity. Novartis intends to integrate Avidity's core business, focusing on its AOC platform and late-stage neuromuscular disease programs, while preserving Avidity's capabilities and ensuring business continuity.

Management Comments

• "What you've built at Avidity—the AOC platform and the late-stage programs in DM1, FSHD and DMD—is remarkable." (Vasant Narasimhan, Novartis CEO)
• "You've taken on some of the most devastating neuromuscular diseases and brought genuinely new science to the brink of transforming patients' lives." (Vasant Narasimhan, Novartis CEO)
• "We are proposing this transaction precisely because of your science and your people." (Vasant Narasimhan, Novartis CEO)
• "Our intent is to collaborate and partner with you to build on what you've created, prioritize business continuity and preserve the capabilities that make Avidity special." (Vasant Narasimhan, Novartis CEO)
• "Until closing, Avidity and Novartis remain separate and independent companies." (Vasant Narasimhan, Novartis CEO)
• "We are committed to being as transparent and timely as possible as decisions are made." (Vasant Narasimhan, Novartis CEO)

Industry Context

This proposed acquisition by Novartis of Avidity Biosciences, coupled with the spin-off of Avidity's cardiology assets, reflects a strategic move by a major pharmaceutical company to bolster its pipeline in specialized therapeutic areas, particularly neuromuscular diseases, leveraging Avidity's innovative AOC platform. The spin-off of early-stage cardiology programs into a separate entity allows for focused development in that area, potentially attracting new investment or partnerships, while Novartis integrates Avidity's more advanced assets. This trend of large pharma acquiring promising biotech firms for platform technologies and late-stage assets, while divesting non-core or early-stage programs, is common in the highly competitive and capital-intensive biopharmaceutical industry.

Stakeholder Impact

• Shareholders: Avidity stockholders will receive consideration for their shares in the merger and will either receive shares of SpinCo or proceeds from its sale. Their approval is required for the merger.
• Employees: Novartis intends to prioritize business continuity and preserve Avidity's capabilities, suggesting a positive outlook for Avidity employees. Novartis executives will engage with employees for integration planning.
• Customers/Patients: The acquisition by Novartis is expected to support the continued development of Avidity's late-stage programs in neuromuscular diseases (DM1, FSHD, DMD), potentially accelerating patient access to new therapies. SpinCo will continue to develop early-stage precision cardiology programs.
• Business Partners: The transactions may cause disruption to existing business relationships, and certain SpinCo assets are subject to a right of first negotiation with an existing collaboration partner.

Next Steps

• Avidity to file a definitive proxy statement with the SEC.
• Definitive proxy statement and proxy card to be delivered to Avidity stockholders.
• Special meeting of Avidity stockholders to approve the transactions.
• Satisfaction of customary closing conditions, including regulatory approvals.
• Novartis Chief People and Organization Officer, Rob Kowalski, to visit Avidity in January (likely 2026).
• Novartis Head of Biomedical Research, Fiona Marshall, to visit Avidity in February (likely 2026).
• Integration planning between Avidity and Novartis after closing.
• Completion of the pre-closing reorganization and Spin-Off of Atrium Therapeutics, Inc.

Key Dates

Keywords

Avidity Biosciences, Novartis, Merger, Acquisition, Spin-Off, Atrium Therapeutics, Precision Cardiology, AOC platform, DM1, FSHD, DMD, Biotechnology, Pharmaceuticals, SEC Filing, DEFA14A, Corporate Governance